BROVANA® (arformoterol tartrate) is for patients with moderate to very severe chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema, who may benefit from treatment with a nebulized long-acting bronchodilator.
12-hour bronchodilation, few daily troughs1
While some tolerance to the bronchodilator effect was observed after 6 weeks of dosing (at the end of the dosing interval), it was not accompanied by other clinical manifestations of tolerance.1,6
Improved overall COPD symptoms2
From pooled analysis of two identical 12-week trials assessing BROVANA 15 mcg twice daily vs placebo.
More symptom-free nights vs placebo3
BROVANA, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, blood pressure, and/or symptoms.
Fewer exacerbations vs placebo4
In two 12-week trials assessing BROVANA 15 mcg twice daily vs placebo. BROVANA should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition.
Improved lung function within minutes5
BROVANA is not indicated for the treatment of acute episodes of bronchospasm, ie, rescue therapy, and does not replace fast-acting rescue inhalers. Median time to 15% increase in FEV1 was 6.7 minutes.
Reduced use of rescue medication2
BROVANA should not be used in conjunction with other inhaled, long-acting beta2-agonists. BROVANA should not be used with other medications containing long-acting beta2-agonists.
Reduced dyspnea vs placebo1,6,7
As with other inhaled beta2-agonists, BROVANA can produce paradoxical bronchospasm that may be life-threatening.
Well tolerated with a proven safety profile5,8
The five most common adverse events reported with frequency ≥2% in patients taking BROVANA, and occurring more frequently than in patients taking placebo, were pain (8% vs 5%), chest pain (7% vs 6%), back pain (6% vs 2%), diarrhea (6% vs 4%), and sinusitis (5% vs 4%).
Covered under Medicare Part B*
−No prior SABA use required
*No guarantee of coverage